OCRELIZUMAB
Tracking # 20-1060204
$99999.00
There are no ratings for this course
Learn more Educator STATPEARLS PUBLISHING, LLC
CE Broker Reporting Reported automatically
Method Computer-Based Training
Course overview
OCRELIZUMAB IS A MEDICATION USED IN THE MANAGEMENT AND TREATMENT OF PRIMARY PROGRESSIVE AND RELAPSING MULTIPLE SCLEROSIS. IT IS IN THE ANTI-CD20 MONOCLONAL ANTIBODY CLASS OF MEDICATIONS. THIS ACTIVITY DESCRIBES THE INDICATIONS, ACTION, AND CONTRAINDICATIONS FOR OCRELIZUMAB AS A VALUABLE AGENT IN MULTIPLE SCLEROSIS MANAGEMENT. THIS ACTIVITY WILL HIGHLIGHT THE MECHANISM OF ACTION, ADVERSE EVENT PROFILE, AND OTHER KEY FACTORS (E.G., ADMINISTRATION, CONTRAINDICATIONS, MONITORING, TOXICITY) PERTINENT FOR INTERPROFESSIONAL TEAM MEMBERS IN THE CARE OF PATIENTS WITH MULTIPLE SCLEROSIS.
Subject areas
This course counts toward the state boards and subject areas below.
Bahamas Medical Council
Specialty Medical Practitioner
1h
General Medicine
Louisiana State Board of Medical Examiners - Physicians & Surgeons
Physician & Surgeon
1h
Category I CME
Mississippi State Board of Medical Licensure
Medical Doctor
1h
AMA Category I
Physician Assistant
1h
AMA Category I
State Medical Board of Ohio
Doctor of Medicine
1h
AMA Category I